Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

MONJUVI

TAFASITAMAB-CXIX

Standard Dose
12MG/KG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview MONJUVI is listed in Drugs@FDA under application 761163 (BLA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient TAFASITAMAB-CXIX Form and strength SOLUTION;INTRAVENOUS - 12MG/KG Sponsor MORPHOSYS US INC Submission history Latest submission status date: 2025-06-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview MONJUVI is listed in Drugs@FDA under application 761163 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient TAFASITAMAB-CXIX Form and strength SOLUTION;INTRAVENOUS - 12MG/KG Sponsor MORPHOSYS US INC Submission history Latest submission status date: 2025-06-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.